"HCC: the Barcelona clinic liver cancer (BCLC) group recommendations 3 have been widely adopted for HCC treatment decision and percutaneous ablation is recommended, as an alternative to surgery, for:"
"reported post-ablation self-limiting symptoms include"
"post-procedural complications include"
"stage A (performance status 0-2 and Child-Pugh score A-C) - early stage: solitary lesion >2 cm or early multifocal disease characterised by up to 3 lesions measuring less than 3 cm"
"poor patient performance status (ECOG >3)"
Expected headings
"Preprocedural evaluation"
"Percutaneous liver tumour ablation techniques are well-established and effective therapeutic alternatives for the treatment of primary and secondary liver tumours. Hepatocellular carcinoma (HCC) and colorectal oligometastatic disease are the most common indications. There are specific indications and contraindications, but the techniques are mostly limited to small oligonodular and favourably-located lesions."